HPV infection and nose, mouth and throat cancers: what do we need to know?
Aurora Mirabile
Biography
Dr. Aurora Mirabile is the head for the Head and Neck Cancer Diagnosis and Treatment Section in the Division of Medical Oncology at IRCCS Ospedale San Raffaele in Milan, Italy, and also a teacher in the School of Otolaryngology.
After graduating in Medicine and Surgery from the University of Milan Bicocca in 2006, she specialized with honors in Medical Oncology at the University of Milan in 2009.
From 2009 to 2014, she was a Medical Oncologist at SS Medical Treatment of Head and Neck Tumors at the National Cancer Institute in Milan, Italy. From 2015 to 2017, she was a Level I Medical Director of SC Medical Oncology at Azienda Ospedaliera Sant'Antonio Abate Gallarate (VA), ASST Valleolona, dealing mainly with cancers of the head and neck and gastroenteric district.
Since 2017, she has been employed under a freelance consulting contract at the Department of Medical Oncology, Ospedale San Raffaele in Milan, Italy, as a Referral for the diagnosis and treatment of head and neck district cancers, and from 2021 as the Head.
Over the years, Dr. Mirabile has developed a special interest in head and neck neoplasms, evidence-based medicine, clinical methodology in oncology, and quality of life. Specifically, her target organs are oral cavity (mouth), oropharynx (tongue base, tonsils and soft palate), nasopharynx (back of the nose), sinuses and nasal cavities, larynx, hypopharynx and salivary glands.
She is also responsible for the diagnostic/therapeutic pathway of these patients, collaborating with ENT surgeons and radiation therapists as well as radiologists, nuclear physicians, and anatomopathologists, to optimize their care plan and ensure access to more precise, specific, and effective technologies, modalities, and therapies. In addition, she coordinates the multidisciplinary activities of various specialties to support the patient (e.g., nutritionist, geriatrician, psychologist, dentist, vulnologist) so as to optimize quality of life and ensure the necessary care throughout the treatment pathway.
Dr. Mirabile is also Principal Investigator of phase III clinical trials with new biologic and immunotherapeutic drugs in both locally advanced and metastatic disease, so that patients can be given increasingly cutting-edge treatments.
She is an author and co-author of 52 publications for Extenso, abstracts and book chapters in international and national journals, as well as principal investigator and sub-investigator in more than 40 Clinical Trials in GCP. Dr. Mirabile is an active member of national and international oncology associations such as ESMO, AIOCC, AIOM, ECHNO, EORTC and NICSO.